Underdetection of clinical benign prostatic hyperplasia in a general medical practice

Journal of General Internal Medicine

Volumn 11, Issue 9, 1996, Pages 513-518

  McNaughton Collins, Mary F ^a   Friedman, Robert H ^a   Ash, Arlene ^a   Hall, Ruth ^a   Moskowitz, Mark A ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

benign prostatic hyperplasia; bother; lower urinary tract symptoms; men's health; quality of life

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; GENERAL PRACTICE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION PROCESSING; MALE; MEDICAL RECORD; PROSTATE HYPERTROPHY; QUALITY OF LIFE; URINARY TRACT DISEASE; UROLOGIC EXAMINATION;

EID: 10244247679     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02599597     Document Type: Article

References (57)

1. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:495-507.
2. Barry MJ, Boyle P, Garraway M, et al. Epidemiology and natural history of BPH. In: Cockett ATK, Khoury S, Aso Y, et al., eds. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Channel Islands: Scientific Communication International Ltd; 1993.
3. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85-9.
4. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology. 1993;42:36-41.
5. Diokno AC, Brown MB, Goldstein N, Herzog AR. Epidemiology of bladder emptying symptoms in elderly men. J Urol. 1992;148: 1817-21.
6. Meyhoff HH, Hald T. Are doctors able to assess prostatic size? Scand J Nephrol. 1978;12:219-21.
7. Girman CJ, Panser LA, Chute CG, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol. 1993;150:887-92.
8. Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology. 1994;44:153-5.
9. Watanabe H, Ohe H, Inaba T, Itakura Y, Saitoh M, Nakao M. A mobile mass screening unit for prostatic disease. Prostate. 1984;5:559-65.
10. Berry SJ, Colley DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132: 474-9.
11. Lytton B, Emery JM, Harvard BM. The incidence of benign prostatic obstruction. J Urol. 1968;99:639-45.
12. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate. 1989;2(suppl):33-50.
13. Garraway WM, Collins GN, Lee KJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338:469-71.
14. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985;121:78-90.
15. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate. 1990; 16:253-61.
16. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241-6.
17. Barry MJ, Mulley AG, Fowler FJ, Wennberg JW. Watchful waiting vs immediate transurethral resection for symptomatic prostatism - the importance of patients' preferences. JAMA. 1988; 259:3010-17.
18. Barry MJ, Fowler FJ. The methodology for evaluating the subjective outcomes of treatment for benign prostatic hyperplasia. Adv Urol. 1993;6:83-99.
19. Fowler FJ, Barry MJ. Quality of life assessment for evaluating benign prostatic hyperplasia treatments. Eur Urol. 1993;24(suppl): 24-7.
20. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health stains in men with benign prostatic hyperplasia. Med Care. 1995;33:AS145-55.
21. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment: Clinical Practice Guideline. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services: February 1994. AHCPR publication 94-0582; No. 8.
22. Tsang KK, Garraway WM. Impact of benign prostatic hyperplasia on general well-being of men. Prostate. 1993;23:1-7.
23. Hunter DWJ, McKee M, Black NA, Sanderson CFB. Health status and quality of life of British men with lower urinary tract symptoms: results from the SF-36. Urology. 1995;45:962-71.
24. Garraway WM, Russell EBAW, Lee RJ, Collins GN. Impact of previously unrecognized benign prostatic hyperplasia on the lives of middle-aged and elderly men. Br J Gen Pract. 1993;43:318-21.
25. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology. 1993;42:663-71.
26. Jacobsen SJ, Guess HA, Panser L, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. Arch Fam Med. 1993;2:729-35.
27. Beier-Holgers R, Bruun J. Voiding pattern of men 60-70 years old: population study in an urban population. J Urol. 1990;143:531-2.
28. Roberts RO, Chute CG, Rhodes T, et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology. 1994;43:621-8.
29. Jacobsen SJ, Girman C-J, Guess HA, et al. Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men. Urology. 1995;45:64-9.
30. Simpson RJ, Lee RJ, Garraway WM, King D, McIntosh I. Consultation patterns in a community survey of men with benign prostatic hyperplasia. Br J Gen Pract. 1994;44:499-502.
31. Lepor H. Medical therapy for benign prostatic hyperplasia. Urology. 1993;42:483-501.
32. Monda JM, Oesterling JE. Medical treatment of benign prostatic hyperplasia: 5-alpha-reductase inhibilors and alpha-adrenergic antagonists. Mayo Clin Proc. 1993;68:670-9.
33. Carlton GE, Altwein JE, Fortuno RF, et al. Benign prostatic hyperplasia professional and public education. In: Cockett ATK, Khoury S, Aso Y, et al., eds. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey, Channel Islands: Scientific Communication International Ltd; 1993.
34. Harry MJ. Medical outcomes research and benign prostatic hyperplasia. Prostate. 1990;3(suppl):61-74.
35. Wennberg JE, Mulley AG, Hanley D, et al. An assessment of prostatectomy for benign urinary tract obstruction: geographic variations and the evaluation of medical care outcomes. JAMA. 1988;259:3027-30.
36. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549-57.
37. Abrams P. New words for old: lower urinary tract symptoms for "prostatism." BMJ. 1994;308:929-30.
38. O'Leary MP, Barry MJ, Fowler FJ. Hard measures of subjective outcomes: validating symptom indexes in urology. J Urol. 1992;148:1546-8.
39. Barry MJ, Fowler FJ, O'Leary MP, et al. Correlation of the American Urological Association symptom index with sell-administered versions of the Madsen-Iversen, Boyarsky, and Maine Medical assessment program symptom indexes. J Urol. 1992;148:1558-63.
40. McKelvie GB, Collins GN, Hehir M, Rogers ACN. A study of benign prostatic hyperplasia - a challenge to British urology. Br J Urol. 1993;71:38-42.
41. Barry MJ. Guidelines: physicians in the lead. Health Manage Q. 1991;13:20-3.
42. Eisenberg JM. The internist as gatekeeper: preparing the general internist for a new role. Ann Intern Med. 1985;102:537-43.
43. Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med. 1995;332:99-109.
44. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hypertrophy. N Engl J Med. 1995;332:75-9.
45. Wennberg J, Gittelson A. Variations in medical care among small areas. Sci Am. 1982;246:120-34.
46. Mulley AG. Assessing patients' utilities: can the end justify the means? Med Care. 1989;27:S269-81.
47. Wennberg JK. The road to guidelines. Health Manage Q. 1991; 13:2-7.
48. Mulley AG. Finding common ground. Health Manage Q. 1991; 13:16-9.
49. Fowler FJ, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Hanley D. Symptom status and quality of life following prostatectomy. JAMA. 1988;259:3018-22.
50. Flood AB, Black NA, McPherson K, Smith J, Williams G. Assessing symptom improvement after elective prostatectomy for benign prostatic hypertrophy. Arch Intern Med. 1992;152:1507-12.
51. Barry MJ, Fowler FJ, Mulley AG, Henderson JV, Wennberg JE. Patient reactions to a program designed to facilitate patient participation in treatment decisions for benign prostatic hyperplasia. Med Care. 1995;33:771-82.
52. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med. 1995;155:477-81.
53. Roberts RG. BPH: new guidelines based on symptoms and patient preference. Geriatrics. 1994;49:24-31.
54. Chapple CR. Correlation of symptomatology, urodynamics, morphology and size of the prostate in benign prostatic hyperplasia. Curr Opin Urol. 1993;3:5-9.
55. Barry MJ, Cockett ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993;150:351-8.
56. Jensen KME, Jorgensen JB, Mogensen P, Bille-Brahe NE. Some clinical aspects of uroflowmetry in elderly males: a population survey. Scand J Urol Nephrol. 1986;20:93-9.
57. Goldman L. Enlightened individual choice vs the public health: rational prevention from whose perspective? J Gen Intern Med. 1995;10:147-50.